title: What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?
abstract: Platelet transfusion therapy is an integral part of modern oncological practice and is used to treat hemorrhage associated with thrombocytopenia. More commonly, platelets are transfused to prevent hemorrhage in thrombocytopenic patients. Conventional wisdom has suggested a threshold for prophylactic transfusion of <20x10(9)/l. Many studies now support the safety of more conservative transfusion regimes that reduce patient exposure to donors and conserve precious resources, without an increase in risk of hemorrhage. This review presents the data to support the use of a prophylactic transfusion threshold of <10x10(9)/l in patients without risk factors for hemorrhage and who have ready access to emergent medical care.
authors: Dana Farber/Partners Cancer Care, Harvard Medical School, Boston, MA, USA. rbenjamin@partners.org
authors: Richard J
authors: RJ
authors: Benjamin
authors: Kenneth C
authors: KC
authors: Anderson
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D006801:Humans; D010976:Platelet Count; D017713:Platelet Transfusion / Q000379:methods / Q000592:standards*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000150:complications / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents